A Phase III Trial to Test the Efficacy of ZD4054, an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.

Next Previous
Trial Profile

A Phase III Trial to Test the Efficacy of ZD4054, an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Zibotentan (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ENTHUSE-M1
  • Sponsors AstraZeneca

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Feb 2016 Last checked against ClinicalTrials.gov record.
    • 11 Feb 2016 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top